MediWound to Report First Quarter 2024 Financial Results
MediWound to Report First Quarter 2024 Financial Results
Conference Call and Webcast Scheduled for Wednesday, May 29th at 8:30 am Eastern Time
將於美國東部時間5月29日上午8:30舉行電話會議和網絡直播
YAVNE, Israel, May 22, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will release its financial results for the first quarter ended March 31, 2024 on Wednesday, May 29, 2024.
以色列雅夫內,2024年5月22日 /美通社/——全球創新酵素組織修復治療領導者mediwound(Nasdaq:MDWD)宣佈,公司將於2024年5月29日(週三)發佈2024年3月31日結束的第一季度財務報告。
Following the release, management will host a conference call and live webcast at 8:30 am Eastern Time to discuss the financial results, provide corporate updates, and answer questions.
報告發布後,管理層將於美國東部時間上午8:30舉行電話會議和網絡直播,討論財務結果、提供公司更新事項並回答問題。
Dial-in and call details are as follows:
撥打電話的詳細信息如下:
Conference Call & Webcast Details | |
Toll-Free: | 1-833-630-1956 |
Israel: | 1-80-921-2373 |
International: | 1-412-317-1837 |
Webcast: | Click HERE |
電話會議和網絡研討會詳情 | |
免費電話: | 1-833-630-1956 |
以色列: | 1-80-921-2373 |
國際: | 1-412-317-1837 |
網絡直播: | 點擊這裏 |
To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. An archived version of the webcast will be available for replay on the Investors section of the MediWound website.
參與者應在電話會議開始前至少5分鐘撥打上述適用的電話號碼。
About MediWound
關於mediwound
MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The Company specializes in the development, production and commercialization of rapid and effective biologics that improve existing standards of care and patient experiences, while reducing costs and unnecessary surgeries.
mediwound(Nasdaq:MDWD)是全球非手術組織修復創新酵素治療領域的領導者。公司專注於開發、生產和銷售快速而有效的生物製品,以提高現有的護理標準和患者體驗,並降低成本和不必要的手術。
MediWound's first drug, NexoBrid, is an FDA and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, which can significantly reduce surgical interventions. Utilizing the same core biotherapeutic enzymatic platform technology, MediWound has developed a strong R&D pipeline, including the company's lead drug under development, EscharEx. EscharEx is a Phase III-ready biologic for the debridement of chronic wounds, offering significant potential advantages over the dominant $360+ million product and an opportunity to expand the market.
MediWound的第一款藥物NexoBrid是FDA和EMA批准的孤兒藥物,用於深度部分厚度和/或全厚度燒傷的疤痕清除,可以顯著減少手術干預。利用相同的核心生物治療酵素平台技術,MediWound已經開發出了一個強大的研發管線,包括公司正在研製的領先藥物EscharEx。EscharEx是一種第三期臨床試驗的生物製品,可用於清除慢性傷口,具有顯着的潛在優勢,可以擴大市場規模。
For more information visit www.mediwound.com and follow the Company on LinkedIn.
獲取更多信息,請訪問www.mediwound.com並在社交媒體上關注公司。LinkedIn.
MediWound Contacts: | |
Hani Luxenburg | Daniel Ferry |
Chief Financial Officer | Managing Director |
MediWound Ltd. | LifeSci Advisors, LLC |
ir@mediwound.com | daniel@lifesciadvisors.com |
Media Contact: | |
Ellie Hanson | |
FINN Partners for MediWound | |
ellie.hanson@finnpartners.com | |
929-588-2008 |
MediWound聯繫人: | |
Hani Luxenburg | Daniel Ferry |
致富金融 | 董事總經理 |
MediWound Ltd. | LifeSci Advisors,LLC |
ir@mediwound.com | daniel@lifesciadvisors.com |
媒體聯繫人: | |
Ellie Hanson | |
MediWound的FINN合作伙伴 | |
ellie.hanson@finnpartners.com | |
929-588-2008 |
譯文內容由第三人軟體翻譯。